- Product Details
Keywords
- 4-Pyrimidinamine, 2,5-dichloro-N-[2-[(1-methylethyl)sulfonyl]phenyl]-
- Chiral compound
- commercial production from grams to tons, with technical documents support and audit/inspection support
Quick Details
- ProName: Ceritinib intermediate, LDK378 interme...
- CasNo: 761440-16-8
- Molecular Formula: C13H13Cl2N3O2S
- Appearance: powder to crystal
- Application: Ceritinib intermediate, LDK378 interme...
- DeliveryTime: within 4 weeks
- PackAge: standard package
- Port: TBC
- ProductionCapacity: commercial production Metric Ton/Day
- Purity: 99%
- Storage: Keep in dark place,Sealed in dry,Room ...
- Transportation: Non-hazardous
- LimitNum: 10 Gram
- Moisture Content: ≤0.5%
- Impurity: ≤1.0%
Superiority
Self Innovation
Multi-target purpose intermediate with wide usage
Commercial production from grams to tons, with technical documents package support, and audit and inspection support.
With high purity and optimized and stable process.
Details
MW: 346.23
Self Innovation
SENOVA PHARMA is committed to the development and production of API’s, advanced intermediates and biochemical products.
We insist on product development and production technology platform combining chemical synthesis (drug synthesis) technology, enzyme synthesis (biocatalytic and biotransformation) technology and microbial fermentation (biosynthesis) technology.
Our own production base and our cooperative plants in China produce products according to cGMP application, providing customers with stable and reliable whole-chain solutions, esp in anti-tumor and anti-cancer fields.